Last updated: 2026-09-09 04:30:01. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Myriad Genetics Inc. (MYGN) operates in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector and is listed on NASDAQ. The stock is currently priced at $3.18, with a market capitalization of $305.12M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.74 to $8.59. This page covers its latest market performance, valuation, price trends and company information.
$305.12M | |
$3.18 | |
$50.44 | |
$2.74 | |
$3.19 | |
962.41K | |
1.82M | |
-- | |
$8.59 | |
$2.74 | |
-- | |
-- |
Myriad Genetics Inc. (MYGN) last closed at $3.19 as of 2026-09-08 23:31:00, unchanged from the previous close of $3.19.
During the latest regular trading session, MYGN traded between $2.74 and $50.44, with a volume of 962.41K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Myriad Genetics Inc. (MYGN) moved from $3.18 to $3.18, representing a decline of 0.16% ($0.01).
The stock traded between $2.92 and $3.35 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 1.49 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 7.4%
MYGN is currently trading at $3.18, placing it 7.4% of the way from its 52-week low of $2.74 to its 52-week high of $8.59. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
| Industry | IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES |
| Employees | 2700 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Myriad Genetics Inc. (MYGN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.